Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis.
haemodialysis
intoxication
oxcarbazepine
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
24
07
2021
received:
22
07
2021
accepted:
25
07
2021
pubmed:
30
7
2021
medline:
5
3
2022
entrez:
29
7
2021
Statut:
ppublish
Résumé
Oxcarbazepine (OXC) is an antiepileptic drug. Patients suffering from chronic kidney disease with an estimated glomerular filtration rate below 30 ml/min/1.73 m A 31-year-old man was admitted with a history of diplopia, ataxia and dizziness attacks that had disappeared after a regular haemodialysis sessions for three months. Medical history was remarkable for primary antiphospholipid syndrome (APS). However, no signs of new-onset APS-related neurological involvement were present. Then, it was revealed that the patient had been using 2400 mg/day of OXC for four months, despite the prescription of half of this dose. Serum OXC level was 50 mcg/ml (reference: 3-35 mcg/ml) before a regular haemodialysis session. All symptoms disappeared in a few days after reducing to 1200 mg/day and never recurred. We reported a chronic OXC intoxication in a patient on maintenance haemodialysis. To the best of our knowledge, it is the first chronic OXC intoxication case in the literature. It could be related to episodic removal of OXC and its metabolites via haemodialysis. Consequently, dose modification of drugs is a pivotal point in haemodialysis patients. Chronic drug intoxications must be kept in mind in haemodialysis patients with unexplained symptoms.
Substances chimiques
Anticonvulsants
0
Oxcarbazepine
VZI5B1W380
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-259Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Phelps SJ, Wheeles JW. Oxcarbazepine: a brief review. J Pediatr Pharmacol Ther. 2005;10:248-253.
Beydoun A. Safety and efficacy of oxcarbazepine: results of randomized, double-Blind trials. Pharmacotherapy. 2000;20:152S-158S.
Musso CG, Vilas M, Aparicio C, et al. Oxcarbazepine induced hyponatremia: A potential explanation of its physiopathology. Electron J Biomed. 2009;1:32-35.
Karasu E, Baktir AO. Three Types of Atrioventricular Block Induced by Oxcarbazepine in a Young Adult. Klin Psikofarmakol B. 2013;23(1):84-88.
Orozco B, Garlich F, Hick J. Oxcarbazepine Overdose Causing an Accelerated Junctional Rhythm with Atrioventricular Dissociation. Clin Toxicol. 2010;48:657.
Jamaldeen J, Basheer A, Sarma AC, Kandasamy R. Prevalence and patterns of hearing loss among chronic kidney disease patients undergoing haemodialysis. Australas Med J. 2015;8:41-46.
Jourde-Chiche N, Mancini J, Dagher N, et al. Antimalarial ototoxicity: an underdiagnosed complication? A study of spontaneous reports to the French Pharmacovigilance Network. Ann Rheum Dis. 2012;71:1586. https://doi.org/10.1136/annrheumdis-2011-201265
Erez D, Abarbuch E, Natour A, et al. Audiological disturbances in patients with primary antiphospholipid syndrome. Lupus. 2020;29:533-538.
Pedrini M, Noguera A, Vinent J, Torra M, Jiemenez R. Acute oxcarbazepine overdose in an autistic boy. Br J Clin Pharmacol. 2009;67:579-581.
Furlanut M, Franceschi L, Poz D, Silvestri L, Pecorari M. Acute oxcarbazepine, benazepril and hydrochlorothiazide overdose with alcohol. Ther Drug Monit. 2006;28:267-268.
Christensen J, Balsley T, Villadsen J, Heinsvig EM, Dam M, Poulsen JH. Removal of 10-hydroxycarbazepine by plasmapheresis. Ther Drug Monit. 2001;23:374-379.